v3.26.3
Segments - Schedule of Segment Revenue and Expenses to Consolidated Net Loss (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2026
Jun. 30, 2026
Mar. 31, 2026
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2026
Sep. 30, 2025
Direct research and development expenses by program:                
Selling, general and administrative $ 21,308     $ 16,172     $ 59,400 $ 47,495
Interest income (4,183)     (1,821)     (9,075) (6,012)
Net loss (45,489) $ (43,423) $ (41,284) (34,386) $ (41,443) $ (35,907) (130,196) (111,736)
Operating Segments [Member]                
Direct research and development expenses by program:                
Personnel-related research and development [1] 10,741     7,941     29,477 24,506
Selling, general and administrative 21,308     16,172     59,400 47,495
Interest income (4,183)     (1,821)     (9,075) (6,012)
Other segment items [2] 14     180     142 1,062
Net loss (45,489)     (34,386)     (130,196) (111,736)
Operating Segments [Member] | Avexitide                
Direct research and development expenses by program:                
Total direct research and development expenses by program [3],[4] 10,661     4,886     30,009 17,417
Operating Segments [Member] | AMX0035 - PSP                
Direct research and development expenses by program:                
Total direct research and development expenses by program [3],[4] (425)     2,995     260 14,704
Operating Segments [Member] | Other programs                
Direct research and development expenses by program:                
Total direct research and development expenses by program [5] $ 7,373     $ 4,033     $ 19,983 $ 12,564
[1] The Company does not allocate personnel and other similar costs to specific programs because these costs are deployed across multiple programs.
[2] Other segment items primarily consists of net realized and unrealized losses on foreign exchange transactions.
[3] Depreciation and amortization expense of less than 0.1 million and $0.2 million during the three and nine months ended September 30, 2026, respectively, and $0.1 million and $0.4 million during the three and nine months ended September 30, 2025, respectively, are allocated across the significant expense captions.
[4] The significant expense categories and amounts align with the segment-level information that is regularly provided to the CODM. As the Company has one reportable segment, there were no intersegment eliminations for the three and nine months ended September 30, 2026 and 2025.
[5] Other programs includes milestone payments totaling $4.0 million made to Gubra following the selection and handover of AMX0318 as a development candidate for PBH and other rare diseases during the nine months ended September 30, 2026.